←
Redeye22,882 posts
Redeye avatar

Redeye

@Redeye_

A members network for financial professionals and private investors. We keep our eyes focused on Nordic Tech and Life Science based companies with global reach.

◷ Joined June 2010▧ 14,000 Photos and videos
Redeye avatar
Redeye@Redeye_·11h

InfraCom: SEK45m cost-savings programme (40 staff, 14%), phased in from Q4, full effect Q3 2027. Needed to restore credibility in the 12–15% EBITA-margin target after Q3's 7.6%. EBITA estimates raised 2–18%. Fair value in the report. $INFRA redeye.se/research/1193846/i…

Post attachment
Redeye avatar
Redeye@Redeye_·15h

Redeye interviewed Neola Medical’s CEO, Hanna Sjöström, following the company’s Q3 2026 report. We discussed the report, the Breakthrough Device Designation and upcoming studies for the Neola device. $NEOLA redeye.se/research/1193796/n…

Post attachment
Redeye avatar
Redeye@Redeye_·15h

Lytix raised NOK80m at NOK8.00 (~12% dilution), ~80% from top holders, removing the financing overhang before full NeoLIPA data at ESMO IO (15 Dec). Runway into Q4 2027; phase III still needs a partner. Fair value in the report. $LYTIX redeye.se/research/1193777/l…

Post attachment
Redeye avatar
Redeye@Redeye_·16h

Smart Eye Q3: sales in line (+33% organic), all profit measures beat; first positive EBIT since 2015. Auto license revenue +150% y/y; royalties down q/q (seasonal). SEK40m savings programme from 2027. Fair value in the report. $SEYE redeye.se/research/1193654/s…

Post attachment
Redeye avatar
Redeye@Redeye_·16h

A cancer vaccine (SELLAS' GPS) showed a survival benefit as AML maintenance in a randomised phase III: median OS 24.0 vs 14.7 months. Supports Mendus' vididencel and its funding/partnering backdrop; not a near-term rival. Fair value in the report. $IMMU redeye.se/research/1193708/m…

Post attachment
Redeye avatar
Redeye@Redeye_·16h

IRLAB Q3: costs below estimate, cash SEK90.6m. A 2026 deal is now less likely; ~30% staff cut, more BD focus. Mesdopetam deal moved to 2027, more dilution. Otsuka-funded LIFT-PD readout mid-2027; cash lasts beyond it. Fair value in the report. $IRLAB redeye.se/research/1193605/i…

Post attachment
Redeye avatar
Redeye@Redeye_·Nov 17

Redeye has interviewed Fable Media Group’s CEO, Carl Magnusson, about the Q3 report highlights, the suspension of operations in Brazil following the provisional ban on online betting and casino, the adjusted guidance and the outlook for new markets and the dividend. $FABLE redeye.se/research/1193539/f…

Post attachment
Redeye avatar
Redeye@Redeye_·Nov 17

ExpreS2ion Q3: revenue/EBIT miss on lower grants; burn in line. Phase I fully enrolled, clean safety, responses in 12 of 13, though strength varies more; readout now Q1 2027. Phase II needs a partner or new equity. Fair value in the report. $EXPRS2 redeye.se/research/1192942/e…

Post attachment
Redeye avatar
Redeye@Redeye_·Nov 17

GiG Software trades below Redeye's Fair Value estimate of SEK 4.7 per share and has Market Edge scores of 4 for Value (Attractively Priced) and 4 for Momentum (Strong). We spoke with our analyst about what he sees as the main challenges with the 888Africa acquisition, what stood out in the Q3 results, and other key topics. This is a premium article, included in our paid plans from SEK 99/month $GIG redeye.se/research/1193612/g…

Post attachment
Redeye avatar
Redeye@Redeye_·Nov 17

Lytix Q3: NeoLIPA met its primary endpoint (interim pCR 44% vs ~20% historically); full data at ESMO IO on 15 Dec. Stronger hand in phase III partnering. Cash into Q2 2027; we assume an equity raise. Base case NOK16 (15), fair value NOK15 (14). $LYTIX redeye.se/research/1193535/l…

Post attachment
Redeye avatar
Redeye@Redeye_·Nov 17

Corline Q3: sales SEK2.4m (+81% y/y), below our estimate but as the soft H2 guidance signalled. Binding rolling Kardium orders improve visibility; we expect a Q4 rebound. Globe ramp slower than we expected. Base case SEK24 (25), fair value SEK19. $CLBIO redeye.se/research/1193418/c…

Post attachment
Redeye avatar
Redeye@Redeye_·Nov 16

Dynavox restated organic growth after inconsistent FX use. IFRS figures, margins and targets unchanged, but Q3 organic growth is now 9% (13%) and N. America 11% (16%): no 2026 acceleration. EBIT margin 17.4% still above target. No estimate changes. $DYVOX redeye.se/research/1193456/d…

Post attachment
Redeye avatar
Redeye@Redeye_·Nov 16

Saniona has FDA clearance to start Phase I of SAN2465, its GABA-A α5 NAM for major depression; first participant before year-end. A positive step that keeps Saniona on track, with both priority programmes soon in the clinic. Q3 report next week. $SANION redeye.se/research/1193444/s…

Post attachment